Corcept Therapeutics | CORT - Selling And Administration Expenses


Corcept Therapeutics reported $114.74M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Alaunos Therapeutics USD 585K 84K Sep/2025
ANI Pharmaceuticals USD 82.79M 6.13M Dec/2025
Ardelyx USD 75.92M 7.69M Dec/2025
Assertio Holdings USD 16.73M 1.66M Sep/2024
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Canopy Growth CAD 28.9M 636K Dec/2025
Corcept Therapeutics USD 114.74M 7.77M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
J&J USD 6.75B 831M Dec/2025
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Merck USD 2.85B 215M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Novartis USD 3.44B 132M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.87M 70K Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Supernus Pharmaceuticals USD 122.39M 57.29M Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025